Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells.
about
From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaA case of Bowen's disease and small-cell lung carcinoma: long-term consequences of chronic arsenic exposure in Chinese traditional medicine.Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancerEnhancement of arsenic trioxide cytotoxicity by dietary isothiocyanates in human leukemic cells via a reactive oxygen species-dependent mechanism.Targeting PML-RARα and Oncogenic Signaling Pathways by Chinese Herbal Mixture Tien-Hsien Liquid in Acute Promyelocytic Leukemia NB4 CellsMEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complexOvercoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignanciesTargeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.Emerging MEK inhibitors.Arsenic trioxide (As2O3) inhibits expression of estrogen receptor-alpha through regulation of the mitogen-activated protein kinase (MAPK) pathway in endometrial cancer cells.Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias.Arsenic in leukemia: a RSKy businessFrequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients.microRNA-23a, -27a and -24 synergistically regulate JAK1/Stat3 cascade and serve as novel therapeutic targets in human acute erythroid leukemia.
P2860
Q24605527-750B2D17-5D9D-4844-BAB7-C6FC26F73DB4Q24814268-2EA90011-55AF-463C-81D6-0A403474CB8BQ27332151-4752DAFB-453A-4AD5-B39C-91F99C0A7D35Q33470967-EF8312F7-D6EF-44CA-AA4D-865FBC9BAF04Q35109736-E955180B-0F1A-4206-BC1F-28F1B1BFA9D3Q36706340-E91B2DC8-78C7-4325-B7A9-067D660788A7Q36812355-AC00573C-E699-4988-AC8F-3D2619355858Q37109225-6AD386AF-0C88-4092-8B05-CCDB71ACDCA7Q37691441-257F1E7C-A80B-4449-B59E-059B976765D7Q39904482-96BC3146-D23C-486C-9EC8-D7D80F549E41Q40382560-169296E2-F9C0-41FB-A6B6-5CE9FF05B941Q41960709-D4299A28-4879-498D-BC65-1AF2BF15494CQ46845164-EC4B98C4-3D1D-45F8-B3E2-B829B7549796Q53120406-4C146A49-022E-4426-B078-895CE65467A2
P2860
Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Arsenic trioxide (ATO) and MEK ...... promyelocytic leukemia cells.
@en
type
label
Arsenic trioxide (ATO) and MEK ...... promyelocytic leukemia cells.
@en
prefLabel
Arsenic trioxide (ATO) and MEK ...... promyelocytic leukemia cells.
@en
P2093
P2860
P356
P1433
P1476
Arsenic trioxide (ATO) and MEK ...... e promyelocytic leukemia cells
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403585
P50
P577
2005-02-01T00:00:00Z
P5875
P6179
1039200326